Clinical Trial Details
| Trial ID: | L6615 |
| Source ID: | NCT01292993 |
| Associated Drug: | 400 Mg Lx4211 |
| Title: | A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy Subjects |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Type 2 Diabetes Mellitus |
| Interventions: | DRUG: 400 mg LX4211|DRUG: 1000 mg metformin |
| Outcome Measures: | Primary: Plasma concentration of LX4211 and metformin after concurrent single-dose administration, Up to 43 days, including screening | Secondary: Urinary glucose excretion, Up to 43 days, including screening|Fasting plasma glucose, Up to 43 days, including screening|Postprandial glucose, Up to 43 days, including screening|Insulin, Up to 43 days, including screening|Peptide YY, Up to 43 days, including screening|Glucagon-like peptide (GLP-1), Up to 43 days, including screening|Glucose-dependent insulinotropic peptide, Up to 43 days, including screening |
| Sponsor/Collaborators: | Sponsor: Lexicon Pharmaceuticals |
| Gender: | ALL |
| Age: | ADULT |
| Phases: | PHASE1 |
| Enrollment: | 18 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2011-02 |
| Completion Date: | |
| Results First Posted: | |
| Last Update Posted: | 2011-03-30 |
| Locations: | Lexicon Investigational Site, San Antonio, Texas, 78209, United States |
| URL: | https://clinicaltrials.gov/show/NCT01292993 |
